A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Identifieur interne : 002326 ( Main/Merge ); précédent : 002325; suivant : 002327A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Auteurs : Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-08-15.
English descriptors
- KwdEn :
- Adult, Aged, Antioxidants (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, MitoQ, Organophosphorus Compounds (therapeutic use), PD, Parkinson Disease (drug therapy), Time Factors, Treatment Outcome, Ubiquinone (analogs & derivatives), Ubiquinone (therapeutic use), mitochondria, neuroprotection, oxidative damage.
- MESH :
- chemical , analogs & derivatives : Ubiquinone.
- chemical , therapeutic use : Antioxidants, Organophosphorus Compounds, Ubiquinone.
- drug therapy : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Time Factors, Treatment Outcome.
Abstract
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23148
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002C80
- to stream Istex, to step Curation: 002C80
- to stream Istex, to step Checkpoint: 000B69
- to stream PubMed, to step Corpus: 001792
- to stream PubMed, to step Curation: 001792
- to stream PubMed, to step Checkpoint: 001A81
- to stream Ncbi, to step Merge: 002C10
- to stream Ncbi, to step Curation: 002C10
- to stream Ncbi, to step Checkpoint: 002C10
Links to Exploration step
ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23148</idno><idno type="url">https://api.istex.fr/document/7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C80</idno><idno type="wicri:Area/Istex/Curation">002C80</idno><idno type="wicri:Area/Istex/Checkpoint">000B69</idno><idno type="wicri:doubleKey">0885-3185:2010:Snow B:a:double:blind</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:20568096</idno><idno type="wicri:Area/PubMed/Corpus">001792</idno><idno type="wicri:Area/PubMed/Curation">001792</idno><idno type="wicri:Area/PubMed/Checkpoint">001A81</idno><idno type="wicri:Area/Ncbi/Merge">002C10</idno><idno type="wicri:Area/Ncbi/Curation">002C10</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C10</idno><idno type="wicri:Area/Main/Merge">002326</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Neurology Department, Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital, Christchurch</wicri:regionArea><wicri:noRegion>Christchurch</wicri:noRegion></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement></placeName></affiliation></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Chemistry Department, University of Otago, Dunedin</wicri:regionArea><wicri:noRegion>Dunedin</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Mitochondrial Biology Unit, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1670">1670</biblScope><biblScope unit="page" to="1674">1674</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><idno type="DOI">10.1002/mds.23148</idno><idno type="ArticleID">MDS23148</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antioxidants (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>MitoQ</term><term>Organophosphorus Compounds (therapeutic use)</term><term>PD</term><term>Parkinson Disease (drug therapy)</term><term>Time Factors</term><term>Treatment Outcome</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term><term>mitochondria</term><term>neuroprotection</term><term>oxidative damage</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term><term>Organophosphorus Compounds</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.23148"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23148</idno><idno type="url">https://api.istex.fr/document/7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C80</idno><idno type="wicri:Area/Istex/Curation">002C80</idno><idno type="wicri:Area/Istex/Checkpoint">000B69</idno><idno type="wicri:doubleKey">0885-3185:2010:Snow B:a:double:blind</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J." last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Neurology Department, Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L." last="Rolfe">Fiona L. Rolfe</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M." last="Lockhart">Michelle M. Lockhart</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M." last="Frampton">Christopher M. Frampton</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch Hospital, Christchurch</wicri:regionArea><wicri:noRegion>Christchurch</wicri:noRegion></affiliation></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D." last="O'Sullivan">John D. O'Sullivan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Medicine, Neurology Research Centre and University of Queensland Clinical School, Royal Brisbane & Women's Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name><affiliation wicri:level="3"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Neurology, Westmead Hospital, Sydney Medical School, University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement></placeName></affiliation></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A. J." last="Smith">Robin A. J. Smith</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Chemistry Department, University of Otago, Dunedin</wicri:regionArea><wicri:noRegion>Dunedin</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P." last="Murphy">Michael P. Murphy</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Medical Research Council Mitochondrial Biology Unit, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M." last="Taylor">Kenneth M. Taylor</name><affiliation wicri:level="1"><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Antipodean Pharmaceuticals, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-08-15">2010-08-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1670">1670</biblScope><biblScope unit="page" to="1674">1674</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82</idno><idno type="DOI">10.1002/mds.23148</idno><idno type="ArticleID">MDS23148</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MitoQ</term><term>PD</term><term>mitochondria</term><term>neuroprotection</term><term>oxidative damage</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double‐blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J" last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Auckland Hospital, Auckland, New Zealand. bsnow@adhb.govt.nz</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Neurology Department, Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L" last="Rolfe">Fiona L. Rolfe</name></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M" last="Lockhart">Michelle M. Lockhart</name></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M" last="Frampton">Christopher M. Frampton</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D" last="O'Sullivan">John D. O'Sullivan</name></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A J" last="Smith">Robin A J. Smith</name></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P" last="Murphy">Michael P. Murphy</name></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M" last="Taylor">Kenneth M. Taylor</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23148</idno><idno type="RBID">pubmed:20568096</idno><idno type="pmid">20568096</idno><idno type="wicri:Area/PubMed/Corpus">001792</idno><idno type="wicri:Area/PubMed/Curation">001792</idno><idno type="wicri:Area/PubMed/Checkpoint">001A81</idno><idno type="wicri:Area/Ncbi/Merge">002C10</idno><idno type="wicri:Area/Ncbi/Curation">002C10</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.</title><author><name sortKey="Snow, Barry J" sort="Snow, Barry J" uniqKey="Snow B" first="Barry J" last="Snow">Barry J. Snow</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Auckland Hospital, Auckland, New Zealand. bsnow@adhb.govt.nz</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Neurology Department, Auckland Hospital, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Rolfe, Fiona L" sort="Rolfe, Fiona L" uniqKey="Rolfe F" first="Fiona L" last="Rolfe">Fiona L. Rolfe</name></author><author><name sortKey="Lockhart, Michelle M" sort="Lockhart, Michelle M" uniqKey="Lockhart M" first="Michelle M" last="Lockhart">Michelle M. Lockhart</name></author><author><name sortKey="Frampton, Christopher M" sort="Frampton, Christopher M" uniqKey="Frampton C" first="Christopher M" last="Frampton">Christopher M. Frampton</name></author><author><name sortKey="O Sullivan, John D" sort="O Sullivan, John D" uniqKey="O Sullivan J" first="John D" last="O'Sullivan">John D. O'Sullivan</name></author><author><name sortKey="Fung, Victor" sort="Fung, Victor" uniqKey="Fung V" first="Victor" last="Fung">Victor Fung</name></author><author><name sortKey="Smith, Robin A J" sort="Smith, Robin A J" uniqKey="Smith R" first="Robin A J" last="Smith">Robin A J. Smith</name></author><author><name sortKey="Murphy, Michael P" sort="Murphy, Michael P" uniqKey="Murphy M" first="Michael P" last="Murphy">Michael P. Murphy</name></author><author><name sortKey="Taylor, Kenneth M" sort="Taylor, Kenneth M" uniqKey="Taylor K" first="Kenneth M" last="Taylor">Kenneth M. Taylor</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antioxidants (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Organophosphorus Compounds (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Time Factors</term><term>Treatment Outcome</term><term>Ubiquinone (analogs & derivatives)</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term><term>Organophosphorus Compounds</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002326 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002326 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:7C140DE6E87C3E20C8E1AE6C2890DC5B83027C82
|texte= A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |